Only $110 million changes hands upfront — that’s the tell. AbbVie’s deal with Plexium to co-develop small-molecule RAS degraders is structured so that $1.34 billion of the headline $1.45 billion figure lives entirely in milestones, with an acquisition option baked in. That’s not a partnership; it’s a prolonged audition AbbVie can walk away from cheaply if the science doesn’t hold.
The RAS space has eaten reputations for decades. Amgen’s sotorasib and Mirati’s adagrasib cracked the KRAS G12C subset, but G12C represents a minority of RAS-driven cancers — the broader KRAS, NRAS, and HRAS mutations remain largely undrugged. Targeted protein degradation is the current best hypothesis for getting at those harder variants, because degraders can potentially eliminate the protein entirely rather than compete with the GTP-binding event at an awkward allosteric site. Plexium’s platform uses molecular glue chemistry to recruit E3 ligases against RAS family members, which is mechanistically distinct from the PROTAC approach and, in theory, better suited to the shallow, undifferentiated surface of RAS. Whether that theoretical advantage survives contact with a tumor microenvironment is exactly what AbbVie is paying $110 million to find out.
The strategic logic is straightforward even if the science isn’t. AbbVie’s oncology portfolio needs depth beyond its antibody-drug conjugate and immunology adjacencies. Humira’s biosimilar erosion is well-documented; Skyrizi and Rinvoq buy time, but neither is an oncology asset. A functional pan-RAS degrader would be one of the most commercially valuable molecules in the industry — RAS mutations appear in roughly 25% of all human cancers, and no one owns that ground. AbbVie isn’t trying to lead the degrader field from a standing start; it’s licensing optionality against a target that, if validated, justifies a full acquisition at terms already partially negotiated.
The single number to watch is Plexium’s IND filing timeline. Molecular glue degraders targeting RAS have not yet reached human trials in any meaningful way. The moment preclinical selectivity and tolerability data are strong enough to support an IND, AbbVie’s acquisition option becomes a live decision — and the $110 million upfront either looks like a bargain or the first installment on an expensive lesson about undruggable targets.
Source link: https://www.fiercebiotech.com/biotech/abbvie-dips-boiling-ras-waters-145b-biobucks-deal-could-end-acquisition
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
